Denis Keohane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Denis Keohane has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Carmen Munteanu7 shared publications
- Thibaud Damy
Dept. of Cardiology, Hôpitaux Universitaires Henri Mondor, AP-HP, Université Paris Est Créteil (UPEC), CEPIA team INSERM U955 ; F-CRIN GRACE, 94000 Créteil
7 shared publications - Francesco Cappelli
Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy
6 shared publications - Eduardo Villacorta
Department of Cardiology, Complejo Asistencial Universitario de Salamanca, P°. de San Vicente 58, 37007 Salamanca, Spain
4 shared publications - Kristen Hsu
13Amyloidosis Research Consortium, Newton, MA
4 shared publications - Lucia Ponti
University of Urbino
4 shared publications
Latest Publications
- 9 May 2024
- Published by Morressier GmbH
Transthyretin amyloid cardiomyopathy among patients with hypertrophic cardiomyopathy: cardiac imaging and electrocardiographic findings from the TTRACK study PB93 (#19)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Transthyretin amyloid cardiomyopathy among patients with hypertrophic cardiomyopathy: cardiac imaging and electrocardiographic findings from the TTRACK study PB93 (#19)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy PC33 (#7)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy PC33 (#7)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Caregiver burden by severity of patient’s heart failure due to transthyretin amyloid cardiomyopathy: results from a large, non-interventional, real-world study PC32 (#6)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Caregiver burden by severity of patient’s heart failure due to transthyretin amyloid cardiomyopathy: results from a large, non-interventional, real-world study PC32 (#6)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study PC30 (#4)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study PC30 (#4)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Differences in cardiac nuclear imaging results with 99mTc-DPD, 99mTc-PYP, and 99mTc-HMDP bone radiotracers in patients with left ventricular hypertrophy of unknown etiology screened for transthyretin amyloid cardiomyopathy in the TTRACK study PB49 (#20)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Differences in cardiac nuclear imaging results with 99mTc-DPD, 99mTc-PYP, and 99mTc-HMDP bone radiotracers in patients with left ventricular hypertrophy of unknown etiology screened for transthyretin amyloid cardiomyopathy in the TTRACK study PB49 (#20)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Clinical red flags associated with transthyretin amyloid cardiomyopathy in patients with unexplained hypertrophic cardiomyopathy: results of the TTRACK study PB50 (#21)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Clinical red flags associated with transthyretin amyloid cardiomyopathy in patients with unexplained hypertrophic cardiomyopathy: results of the TTRACK study PB50 (#21)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy: post hoc analysis of an international survey study PC31 (#5)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- 9 May 2024
- Published by Morressier GmbH
Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy: post hoc analysis of an international survey study PC31 (#5)
**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was | POSTER
- Open Access
- 17 December 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 225
Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
Emerging evidence suggests that several factors can impact disease progression in transthyretin amyloid polyneuropathy (ATTR-PN). The present analysis used longitudinal data from Val30Met patients participating in the tafamidis (selective TTR stabilizer) clinical development program to evaluate the impact of baseline neurologic severity on disease progression in ATTR-PN. A linear mixed-effects model for repeated measures (MMRM) was constructed using tafamidis and placebo data from the intent-to-treat Val30Met population of the original registration study as well as tafamidis data from the two consecutive open-label extension studies. The second extension study is ongoing, but a prospectively-planned interim analysis involving a cleaned and locked database was conducted (cut-off: December 31, 2014). Val30Met patients are presented by treatment groups as those who received tafamidis during the registration and open-label studies (T-T group), or who received placebo during the registration study and were switched to tafamidis in the open-label studies (P-T group). Neurologic functioning was assessed at baseline and subsequent visits using the Neuropathy Impairment Score–Lower Limbs (NIS-LL). The analysis focused on the disease trajectory over the first 18 months of treatment. The T-T (n = 64) and P-T (n = 61) cohorts were predominantly Caucasian and presented with early-stage neurologic disease (mean [standard deviation] baseline NIS-LL values were 8.4 [11.4] and 11.4 [13.5], respectively). The MMRM analysis demonstrated that baseline severity is an independent significant predictor of disease progression in addition to the treatment effect: patients with a lower baseline NIS-LL showed less progression than those with a higher baseline NIS-LL (p < 0.0001). Neurologic progression in the T-T group was less than in the P-T group across all levels of baseline NIS-LL (p = 0.0088), and the degree of separation increased over the 18-month period. Similar results were seen with the NIS-LL muscle weakness subscale. This analysis of patients with Val30Met ATTR-PN demonstrates that neurologic disease progression strongly depends on baseline neurologic severity and illustrates the disease-modifying effect of tafamidis relative to placebo across a range of baseline levels of neurologic severity and treatment durations. These data also underscore the benefit of early diagnosis and treatment with tafamidis in delaying disease progression in ATTR-PN. NCT00409175 , NCT00791492 and NCT00925002 registered 08 December 2006, 14 November 2008 (retrospectively registered), and 19 June 2009, respectively.
- 17 December 2018
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 13 (1) , 225
Open AccessInfluence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy
Emerging evidence suggests that several factors can impact disease progression in transthyretin amyloid polyneuropathy (ATTR-PN). The present analysis used longitudinal data from Val30Met patients participating in the tafamidis (selective TTR stabilizer) clinical development program to evaluate the impact of baseline neurologic severity on disease progression in ATTR-PN. A linear mixed-effects model for repeated measures (MMRM) was constructed using tafamidis and placebo data from the intent-to-treat Val30Met population of the original registration study as well as tafamidis data from the two consecutive open-label extension studies. The second extension study is ongoing, but a prospectively-planned interim analysis involving a cleaned and locked database was conducted (cut-off: December 31, 2014). Val30Met patients are presented by treatment groups as those who received tafamidis during the registration and open-label studies (T-T group), or who received placebo during the registration study and were switched to tafamidis in the open-label studies (P-T group). Neurologic functioning was assessed at baseline and subsequent visits using the Neuropathy Impairment Score–Lower Limbs (NIS-LL). The analysis focused on the disease trajectory over the first 18 months of treatment. The T-T (n = 64) and P-T (n = 61) cohorts were predominantly Caucasian and presented with early-stage neurologic disease (mean [standard deviation] baseline NIS-LL values were 8.4 [11.4] and 11.4 [13.5], respectively). The MMRM analysis demonstrated that baseline severity is an independent significant predictor of disease progression in addition to the treatment effect: patients with a lower baseline NIS-LL showed less progression than those with a higher baseline NIS-LL (p < 0.0001). Neurologic progression in the T-T group was less than in the P-T group across all levels of baseline NIS-LL (p = 0.0088), and the degree of separation increased over the 18-month period. Similar results were seen with the NIS-LL muscle weakness subscale. This analysis of patients with Val30Met ATTR-PN demonstrates that neurologic disease progression strongly depends on baseline neurologic severity and illustrates the disease-modifying effect of tafamidis relative to placebo across a range of baseline levels of neurologic severity and treatment durations. These data also underscore the benefit of early diagnosis and treatment with tafamidis in delaying disease progression in ATTR-PN. NCT00409175 , NCT00791492 and NCT00925002 registered 08 December 2006, 14 November 2008 (retrospectively registered), and 19 June 2009, respectively.
- Open Access
- 2 January 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (1) , 30-36
Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial
Background: Tafamidis, a non-NSAID highly specific transthyretin stabilizer, delayed neurologic disease progression as measured by Neuropathy Impairment Score–Lower Limbs (NIS-LL) in an 18-month, double-blind, placebo-controlled randomized trial in 128 patients with early-stage transthyretin V30M familial amyloid polyneuropathy (ATTRV30M-FAP). The current post hoc analyses aimed to further evaluate the effects of tafamidis in delaying ATTRV30M-FAP progression in this trial. Methods: Pre-specified, repeated-measures analysis of change from baseline in NIS-LL in this trial (ClinicalTrials.gov NCT00409175) was repeated with addition of baseline as covariate and multiple imputation analysis for missing data by treatment group. Change in NIS-LL plus three small-fiber nerve tests (NIS-LL + Σ3) and NIS-LL plus seven nerve tests (NIS-LL + Σ7) were assessed without baseline as covariate. Treatment outcomes over the NIS-LL, Σ3, Σ7, modified body mass index and Norfolk Quality of Life–Diabetic Neuropathy Total Quality of Life Score were also examined using multivariate analysis techniques. Results: Neuropathy progression based on NIS-LL change from baseline to Month 18 remained significantly reduced for tafamidis versus placebo in the baseline-adjusted and multiple imputation analyses. NIS-LL + Σ3 and NIS-LL + Σ7 captured significant treatment group differences. Multivariate analyses provided strong statistical evidence for a superior tafamidis treatment effect. Conclusions: These supportive analyses confirm that tafamidis delays neurologic progression in early-stage ATTRV30M-FAP. Trial registration number: NCT00409175.
- 2 January 2017
- Published by Taylor & Francis in Amyloid
- Vol. 24 (1) , 30-36
Open AccessTafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial
Background: Tafamidis, a non-NSAID highly specific transthyretin stabilizer, delayed neurologic disease progression as measured by Neuropathy Impairment Score–Lower Limbs (NIS-LL) in an 18-month, double-blind, placebo-controlled randomized trial in 128 patients with early-stage transthyretin V30M familial amyloid polyneuropathy (ATTRV30M-FAP). The current post hoc analyses aimed to further evaluate the effects of tafamidis in delaying ATTRV30M-FAP progression in this trial. Methods: Pre-specified, repeated-measures analysis of change from baseline in NIS-LL in this trial (ClinicalTrials.gov NCT00409175) was repeated with addition of baseline as covariate and multiple imputation analysis for missing data by treatment group. Change in NIS-LL plus three small-fiber nerve tests (NIS-LL + Σ3) and NIS-LL plus seven nerve tests (NIS-LL + Σ7) were assessed without baseline as covariate. Treatment outcomes over the NIS-LL, Σ3, Σ7, modified body mass index and Norfolk Quality of Life–Diabetic Neuropathy Total Quality of Life Score were also examined using multivariate analysis techniques. Results: Neuropathy progression based on NIS-LL change from baseline to Month 18 remained significantly reduced for tafamidis versus placebo in the baseline-adjusted and multiple imputation analyses. NIS-LL + Σ3 and NIS-LL + Σ7 captured significant treatment group differences. Multivariate analyses provided strong statistical evidence for a superior tafamidis treatment effect. Conclusions: These supportive analyses confirm that tafamidis delays neurologic progression in early-stage ATTRV30M-FAP. Trial registration number: NCT00409175.
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S19-S20
Features of Transthyretin Cardiomyopathy Patients With 6 Specific Cardiac Genotypes in the THAOS Registry.
- 1 August 2015
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 21 (8) , S19-S20
Features of Transthyretin Cardiomyopathy Patients With 6 Specific Cardiac Genotypes in the THAOS Registry.